Arrowhead Pharmaceuticals (ARWR) News Today $26.34 +0.31 (+1.19%) (As of 12/2/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Arrowhead Pharmaceuticals to Participate in Upcoming December 2024 ConferencesDecember 2 at 7:30 AM | businesswire.comSanford C. Bernstein Has Lowered Expectations for Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock PriceDecember 2 at 1:40 AM | americanbankingnews.comIntech Investment Management LLC Purchases Shares of 34,045 Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)Intech Investment Management LLC acquired a new position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 34,045 shares of the biotDecember 1 at 3:27 AM | marketbeat.comCitigroup Lowers Arrowhead Pharmaceuticals (NASDAQ:ARWR) Price Target to $26.00November 30 at 4:53 AM | americanbankingnews.comFisher Asset Management LLC Has $2.37 Million Stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)Fisher Asset Management LLC grew its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 941.0% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 122,260 shares of the biotechnology company's stock aftNovember 30 at 3:55 AM | marketbeat.comArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q4 2024 Earnings Call TranscriptNovember 29, 2024 | msn.comArrowhead Pharmaceuticals (NASDAQ:ARWR) Price Target Lowered to $24.00 at Sanford C. BernsteinSanford C. Bernstein cut their target price on Arrowhead Pharmaceuticals from $27.00 to $24.00 and set a "market perform" rating for the company in a research note on Friday.November 29, 2024 | marketbeat.comPiper Sandler Lowers Arrowhead Pharmaceuticals (NASDAQ:ARWR) Price Target to $45.00November 29, 2024 | americanbankingnews.comArrowhead Pharmaceuticals (NASDAQ:ARWR) Earns "Buy" Rating from Chardan CapitalNovember 29, 2024 | americanbankingnews.comHold Rating on Arrowhead Pharmaceuticals: Balancing Strategic Advancements with Execution RisksNovember 28, 2024 | markets.businessinsider.comRBC Capital Reaffirms Their Buy Rating on Arrowhead Pharmaceuticals (ARWR)November 28, 2024 | markets.businessinsider.comArrowhead: The Sarepta Partnership Validates RNAi Platform And Reduces RiskNovember 28, 2024 | seekingalpha.comArrowhead Stock Rockets 16% After Major Licensing DealNovember 28, 2024 | finance.yahoo.comArrowhead Pharmaceuticals Faces Distribution Risks with Vanscoy RelianceNovember 28, 2024 | tipranks.comArrowhead Pharmaceuticals (NASDAQ:ARWR) Earns Buy Rating from Chardan CapitalChardan Capital reiterated a "buy" rating and issued a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Wednesday.November 27, 2024 | marketbeat.comArrowhead Pharmaceuticals Reports 2024 Fiscal Year-End ResultsNovember 27, 2024 | finance.yahoo.comArrowhead Pharma Stock Soars Pre-Market On $825M Sarepta Licensing Deal: Retail Activity Hits Year-HighNovember 27, 2024 | msn.comArrowhead Pharmaceuticals Eyes Future Growth with Strategic DealsNovember 27, 2024 | markets.businessinsider.comStrategic Reprioritization and Partnership Propel Arrowhead Pharmaceuticals’ Growth ProspectsNovember 27, 2024 | markets.businessinsider.comArrowhead Pharmaceuticals, Inc. (ARWR) Q4 2024 Earnings Call TranscriptNovember 27, 2024 | seekingalpha.comArrowhead climbs after licensing deal with SareptaNovember 26, 2024 | msn.comSarepta Therapeutics Announces Global Licensing and Collaboration Agreement with Arrowhead Pharmaceuticals for Multiple Clinical and Preclinical siRNA ProgramsNovember 26, 2024 | businesswire.comReviewing PaxMedica (NASDAQ:PXMD) & Arrowhead Pharmaceuticals (NASDAQ:ARWR)November 25, 2024 | americanbankingnews.comAnalysts Set Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Price Target at $45.33November 25, 2024 | americanbankingnews.comArrowhead Pharmaceuticals (ARWR) to Release Quarterly Earnings on TuesdayNovember 25, 2024 | americanbankingnews.comArrowhead Pharmaceuticals (NASDAQ:ARWR) Given Buy Rating at HC WainwrightNovember 24, 2024 | americanbankingnews.comArrowhead Pharmaceuticals Inc. (ARWR): Among the NASDAQ Stocks with Biggest Upside Potential According to AnalystsNovember 22, 2024 | msn.comArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Given Average Recommendation of "Moderate Buy" by BrokeragesShares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the ten brokerages that are presently covering the stock, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold rating anNovember 22, 2024 | marketbeat.comPrincipal Financial Group Inc. Has $5.64 Million Stock Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)Principal Financial Group Inc. lowered its holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 31.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 290,994 sharesNovember 21, 2024 | marketbeat.comArrowhead Pharmaceuticals’ Potential Approval of Clozasiran Drives Buy Rating and $60 Price TargetNovember 21, 2024 | markets.businessinsider.comPiper Sandler Sticks to Its Buy Rating for Arrowhead Pharmaceuticals (ARWR)November 20, 2024 | markets.businessinsider.comArrowhead Pharmaceuticals (ARWR) Set to Announce Earnings on TuesdayArrowhead Pharmaceuticals (NASDAQ:ARWR) will be releasing earnings after the market closes on Tuesday, November 26, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=644935)November 19, 2024 | marketbeat.comArrowhead announces new PALISADE study resultsNovember 19, 2024 | markets.businessinsider.comArrowhead submits plozasiran NDA to FDANovember 19, 2024 | markets.businessinsider.comArrowhead Pharmaceuticals Presents New Data at AHA24 from PALISADE Phase 3 Study and Open-Label Extension from MUIR and SHASTA-2 Studies of PlozasiranNovember 18, 2024 | businesswire.comArrowhead Pharmaceuticals Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment of Familial Chylomicronemia SyndromeNovember 18, 2024 | businesswire.comArrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Price Down 6.3% - Here's What HappenedArrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Price Down 6.3% - Here's WhyNovember 15, 2024 | marketbeat.comPrivium Fund Management B.V. Increases Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)Privium Fund Management B.V. lifted its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 16.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 333,356 shares of the biotechnoloNovember 10, 2024 | marketbeat.comFY2024 Earnings Forecast for ARWR Issued By Leerink PartnrsArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) - Equities research analysts at Leerink Partnrs upped their FY2024 EPS estimates for shares of Arrowhead Pharmaceuticals in a research report issued on Wednesday, November 6th. Leerink Partnrs analyst M. Foroohar now anticipates that theNovember 8, 2024 | marketbeat.comArrowhead Pharmaceuticals to Webcast 2024 Fiscal Year End ResultsNovember 5, 2024 | finance.yahoo.comArrowhead Pharmaceuticals to Participate in Upcoming November 2024 ConferencesNovember 4, 2024 | finance.yahoo.comabrdn plc Has $7.77 Million Stock Holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)abrdn plc raised its stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 61.3% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 401,146 shares of the biotechnology company's stock after buying aNovember 3, 2024 | marketbeat.comArrowhead Launches FCS Awareness CampaignNovember 1, 2024 | baystreet.caArrowhead Pharmaceuticals Launches New Disease Awareness Campaign, ‘We'll Get There Soon,' to Inspire Hope for the Rare Disease Community Affected by Familial Chylomicronemia SyndromeNovember 1, 2024 | businesswire.comInternational Assets Investment Management LLC Acquires New Stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)International Assets Investment Management LLC acquired a new stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 74,439 shares of the biotechnoOctober 31, 2024 | marketbeat.comAssenagon Asset Management S.A. Has $5.68 Million Stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)Assenagon Asset Management S.A. grew its stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 232.5% in the third quarter, according to its most recent disclosure with the SEC. The fund owned 293,083 shares of the biotechnology company's stock after buying an additionalOctober 30, 2024 | marketbeat.comArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Given Average Rating of "Moderate Buy" by BrokeragesArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) has received an average rating of "Moderate Buy" from the ten brokerages that are presently covering the company, MarketBeat reports. Three investment analysts have rated the stock with a hold recommendation and seven have assigned aOctober 28, 2024 | marketbeat.comIonis Pharmaceuticals: Catalysts Due In 2025/2026 Are Extremely CompellingOctober 23, 2024 | seekingalpha.comArrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Price Down 6.4% - Here's WhyArrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Price Down 6.4% - Should You Sell?October 21, 2024 | marketbeat.comBuffington Mohr McNeal Takes Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)Buffington Mohr McNeal purchased a new stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 30,000 shares of the biotecOctober 18, 2024 | marketbeat.com Get Arrowhead Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ARWR and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Is Mocking Elon, But Wait Until They See This Demo (Ad)Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it. Click here to watch this demo and decide for yourself. ARWR Media Mentions By Week ARWR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ARWR News Sentiment▼0.040.87▲Average Medical News Sentiment ARWR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ARWR Articles This Week▼285▲ARWR Articles Average Week Get Arrowhead Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ARWR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Sarepta Therapeutics News Dr. Reddy's Laboratories News Vaxcyte News Catalent News Qiagen News Roivant Sciences News Intra-Cellular Therapies News Revolution Medicines News Ascendis Pharma A/S News Legend Biotech News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ARWR) was last updated on 12/3/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredIs NVDA a sell? Buy this stock instead before Dec 3After months of speculation that Nvidia was "cooling off..." and "running out of steam..." The company is m...Chaikin Analytics | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arrowhead Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arrowhead Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ARWR Stock Alerts